Monopar Therapeutics
MNPR evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $738.1M
What it means
What to watch
Prepared research question
What matters most for MNPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MNPR
Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company developing a late-stage oral treatment for Wilson disease (ALXN1840) and novel radiopharmaceuticals for oncology, including Phase 1 imaging and therapeutic candidates.
Key risk: Pre-revenue, no approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$738.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials for Monopar Therapeutics.
Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company developing a late-stage oral treatment for Wilson disease (ALXN1840) and novel radiopharmaceuticals for oncology, including Phase 1 imaging and therapeutic candidates.
- Cash & equivalents of $52.8M as of 2026-06-30 [sec].
- Net income of -$5.3M as of 2026-06-30 [sec].
- Shareholders' equity of $130.9M as of 2026-06-30 [sec].
- Initiated rolling NDA submission for ALXN1840 (Wilson disease) on July 22, 2026 [news · 2026-08-12].
- Active Phase 1 clinical trials for MNPR-101-Zr (imaging) and MNPR-101-Lu (therapeutic) in advanced cancers [sec_mda · as of 2026-08-12].
What works
- Late-stage ALXN1840 for Wilson disease has initiated a rolling NDA submission, indicating progress toward potential regulatory approval [news · 2026-08-12].
- Management team has prior experience co-founding BioMarin Pharmaceutical and completing multiple drug development and commercialization exits [sec_mda · as of 2026-05-14].
- Company has cash of $52.8M as of 2026-06-30 and states no substantial doubt about its ability to continue as a going concern through at least December 2027 [sec · filed 2026-04-01].
What to weigh
- Company has incurred losses since inception and expects to continue incurring substantial operating losses for the foreseeable future [sec · filed 2026-04-01].
- No therapeutic product has completed development through marketing approval; the company remains pre-revenue from product sales [sec_mda · as of 2026-08-12].
- Expenses are expected to increase substantially as the company advances ALXN1840 commercialization and radiopharmaceutical clinical trials [sec_mda · as of 2026-08-12].
- Additional funding or a pharmaceutical partner may be needed to continue advancing all clinical programs and regulatory activities [sec_mda · as of 2026-03-27].
From the filings
Quoted directly from source documents.
Rolling NDA submission for ALXN1840 initiated July 22, 2026
“On July 22, 2026, Monopar announced it had initiated the rolling submission of a New Dru”
News · August 12, 2026
Company expects to continue incurring substantial operating losses
“The Company has incurred losses since inception and expects to continue to incur substantial operating losses over the next several years.”
SEC filings · April 1, 2026
No therapeutic product has completed development through marketing approval
“As a company, we have not completed development through marketing approvals of any therapeutic products.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue, no approved products — No therapeutic product has completed development through marketing approval; company is pre-revenue from product sales [sec_mda · as of 2026-08-12].
- Continued operating losses — Company has incurred losses since inception and expects substantial operating losses for several more years [sec · filed 2026-04-01].
- Need for additional funding — May need to raise additional funding or find a partner to continue advancing clinical programs and regulatory activities [sec_mda · as of 2026-03-27].
- Increasing expenses ahead — Expenses expected to increase substantially as ALXN1840 commercialization and radiopharmaceutical trials progress [sec_mda · as of 2026-08-12].
What to watch
- Progress of the rolling NDA submission for ALXN1840 and any FDA feedback or approval decision [news · 2026-08-12].
- Data readouts from the Phase 1 MNPR-101-Zr imaging trial and Phase 1a MNPR-101-Lu therapeutic trial in advanced cancers [sec_mda · as of 2026-08-12].
- Cash runway and any new financing or partnership announcements given the expectation of increasing expenses [sec_mda · as of 2026-03-27].
- Preclinical advancement of MNPR-101-Ac (actinium-225 conjugate) toward clinical trials [sec_mda · as of 2026-05-14].
Sources: News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Monopar Therapeutics through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Monopar Therapeutics facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.03
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 10 sells (180d)
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 67.1%
- Days to cover
- 9.0
- Shares short
- 1,684,127
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MNPR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Monopar Therapeutics?
Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company developing a late-stage oral treatment for Wilson disease (ALXN1840) and novel radiopharmaceuticals for oncology, including Phase 1 imaging and therapeutic candidates.
Who is the CEO of Monopar Therapeutics?
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. is the chief executive officer of Monopar Therapeutics (MNPR).
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics (MNPR) is headquartered in Wilmette, IL, United States.
What therapeutic areas does Monopar Therapeutics focus on?
Monopar Therapeutics develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.